Combined with the current study reports, HER2-low is accepted by the majority of the population as a therapeutic subtype in breast cancer treatment, but whether HER2-low can be considered a new molecular subtype is still controversial and still needs to be proved by more and larger studies. This evidence concerns the gene ERBB2 and breast carcinoma.